Research Progress on Financial Toxicity in Bladder Cancer Patients

Bladder cancer, the most prevalent urinary system malignancy, is characterized by high recurrence rates and prolonged treatment. While therapeutic advances have substantially improved survival, they have also heightened the prominence of financial toxicity (FT)-a treatment-related economic burden that severely impairs the quality of life of patients and their families. This review synthesizes evidence on the prevalence, influencing factors, impact on health outcomes, and management strategies of FT in bladder cancer, offering insights for individualized clinical support and health policy refinement. Future research should broaden study populations, employ diverse methodologies, and develop healthcare system-specific interventions to establish a comprehensive FT management framework.